📈 Jumpstart Signal Watchlist — October 09, 2026

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.70 is 8% below 3yr high $12.66 · ⏳ SMA200 $9.09 (current price $11.70 is above) · 💰 Market Cap $2.0B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.5%)
- 🔔 Strong above EMA50 (10.2%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×2).
✅ Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer — Yahoo Finance.
🤖 The FDA granted Fast Track designation to VIR-5500 for late-line metastatic castration-resistant prostate cancer. The designation may help expedite development and review of a pipeline candidate.
✅ H.C. Wainwright raises Vir Biotechnology price target to $22 — Investing.com.
🤖 H.C. Wainwright raised its price target from $20 to $22 while maintaining a Buy rating. The higher target reflects a more favorable analyst outlook.
⚪️ Vir Biotechnology Appoints David Liu as Chief Medical Officer — Business Wire.
🤖 Vir appointed David Liu as executive vice president and chief medical officer, with responsibility for clinical development, medical affairs, and regulatory affairs. This is a leadership change, with no direct financial or clinical outcome reported.
⚪️ Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer — Business Wire.
🤖 Vir announced Aziz Sawaf’s appointment as executive vice president and CFO. The article reports a management change but no new financial results or guidance.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 At/above 3yr high $59.86 (current $59.86) · ⏳ SMA200 $49.34 (current price $59.86 is above) · 💰 Market Cap $14.9B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 3/10
- 🗞️ News sentiment is negative (❌×2 ⚪️×3; showing 4 of 5).
❌ Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib ... — Yahoo Finance.
🤖 The FDA extended its review of zanzalintinib for metastatic colorectal cancer by three months, moving the action date to March 3, 2027. The delay pushes back a potential regulatory decision and commercialization timeline.
❌ Exelixis (NASDAQ:EXEL) Price Target Cut to $45.00 by ... — MarketBeat.
🤖 Royal Bank of Canada lowered its price target from $46 to $45 while maintaining a Sector Perform rating. The reduced target is a modestly negative analyst signal.
⚪️ Post Resch Tallon Group Inc. Sells ... — MarketBeat.
🤖 This article reports a routine institutional ownership filing, which is backward-looking and not a directional catalyst. It also mentions a Citigroup rating reiterated on September 14, but provides no new rating change.
⚪️ Exelixis (NASDAQ:EXEL) Price Target Raised to $54.00 — MarketBeat.
🤖 Truist raised its price target from $52 to $54 but maintained a Hold rating. The higher target is modestly favorable, while the unchanged rating and stated downside to the target make the overall signal mixed.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $63.67 is 9% below 3yr high $69.85 · ⏳ SMA200 $29.85 (current price $63.67 is above) · 💰 Market Cap $3.3B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.4%)
- 🔔 Strong above EMA50 (20.0%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar? — Zacks.
🤖 CareDx shares rose 13% after BTIG raised its price target to $74 from $60 while maintaining a Buy rating. The article also cites strong second-quarter revenue growth, though its discussion of the upcoming earnings report is not treated as a catalyst.
✅ CareDx (NASDAQ:CDNA) Hits New 1-Year High — MarketBeat.
🤖 CareDx reached a new one-year high amid improved analyst sentiment, including BTIG’s September 24 price-target increase to $74 with a Buy rating. The article also notes that the average price target is below the current share price, tempering the positive signal.
⚪️ CareDx (NASDAQ:CDNA) Shares Down 6.2% - Time to Sell? — MarketBeat.
🤖 The article reports a share-price decline and a mixed analyst consensus, but also notes BTIG’s higher $74 price target and Buy rating. It does not identify a new company-specific catalyst that clearly changes the outlook.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 At/above 3yr high $37.19 (current $37.19) · ⏳ SMA200 $26.98 (current price $37.19 is above) · 💰 Market Cap $4.7B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Base breakout (range: 6.5%); Low drawdown (6.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Concentra Group Holdings Parent, Inc. (CON) Hit a 52 Week High, Can the Run Continue? — Zacks via Yahoo Finance.
🤖 The article notes that shares reached a 52-week high and highlights Concentra’s recent earnings beats, including second-quarter EPS and revenue above consensus. It also cites a Strong Buy Zacks Rank and favorable earnings estimate revisions.
✅ Ação da Concentra Group Holdings atinge máxima histórica de US$ 36,80 — Investing.com.
🤖 The article reports that Concentra shares reached a record high and recaps second-quarter revenue growth, adjusted EPS of $0.52, and an increased full-year outlook. It also notes S&P’s credit-rating upgrade and lower leverage.
✅ Concentra Group Holdings Parent (CON) Beats Again And Expands Its Footprint — Yahoo Finance.
🤖 The article highlights Concentra’s August earnings beat and the opening of a new occupational health center in Daytona Beach, expanding its footprint. It also notes that the shares remain below a cited fair-value estimate.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Worthington Enterprises designs and manufactures building and consumer products, including HVAC and water systems, metal roofing and ceiling components, tools, portable propane and helium cylinders, outdoor-living products, and celebration supplies. Its brands include Bernzomatic, Balloon Time, Coleman propane cylinders, Garden Weasel, and LEVEL5 Tools.
- 🎯 Current $62.45 is 7% below 3yr high $67.39 · ⏳ SMA200 $55.51 (current price $62.45 is above) · 💰 Market Cap $3.0B
- WOR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 57/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 978% (>20%); ROE 15% (>15%); Low LT D/E 0.30 (<1.0).
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Worthington Q1 FY27 slides: data center push drives earnings beat — Investing.com.
🤖 Worthington reported adjusted EPS of $0.82 and revenue of $343.9 million, both above analyst expectations. Data-center-related tank revenue reached $13 million in the quarter, highlighting a potential growth opportunity.
✅ Worthington Enterprises Shares Jump 15% on Strong ... — Yahoo Finance.
🤖 The article reports 13.2% year-over-year revenue growth, higher adjusted EBITDA, and nearly doubled free cash flow in fiscal Q1. It also notes share repurchases and the declared quarterly dividend.
⚪️ Worthington Enterprises director John McConnell sells $4.17m in stock — Investing.com.
🤖 The director sold shares after exercising an equal number of stock options, so the reported disposal alone does not establish a directional catalyst for the stock.
🍭 Bonus (B): 0/10 — Steel Works & Blast Furnaces

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $36.40 is 57% below 3yr high $85.47 · ⏳ SMA200 $22.93 (current price $36.40 is above) · 💰 Market Cap $2.7B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (5.6%)
- 🔔 Strong above EMA50 (12.1%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ DA Davidson raises Five9 stock price target on revenue growth — Investing.com.
🤖 DA Davidson raised its price target to $33 from $28 while maintaining a Neutral rating. The higher target reflects optimism about Five9’s revenue growth, though the unchanged rating tempers the positive signal.
✅ Cantor Fitzgerald raises Five9 stock price target to $40 on valuation — Investing.com.
🤖 Cantor Fitzgerald raised its price target to $40 from $34 and maintained an Overweight rating. The higher target is a favorable analyst signal for the stock.
✅ Needham reiterates Buy on Five9 stock, cites AI platform progress — Investing.com.
🤖 Needham reaffirmed its Buy rating and $40 price target after discussions with contact-center technology leaders, citing progress in Five9’s AI platform. The reaffirmed bullish view supports a positive assessment.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)